Literature DB >> 34911792

Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade.

Kok Pin Yong1,2, Ho Jin Kim3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34911792      PMCID： PMC8674934          DOI： 10.1212/NXI.0000000000001110

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN： 2332-7812


× No keyword cloud information.
  17 in total

1.  Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.

Authors:  Pierre Durozard; Audrey Rico; Clémence Boutiere; Adil Maarouf; Romaric Lacroix; Sylvie Cointe; Shirley Fritz; Corinne Brunet; Jean Pelletier; Romain Marignier; Bertrand Audoin
Journal:  Ann Neurol       Date:  2019-11-27       Impact factor: 10.422

2.  Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.

Authors:  Marius Ringelstein; Ilya Ayzenberg; Jens Harmel; Ann-Sophie Lauenstein; Eckart Lensch; Florian Stögbauer; Kerstin Hellwig; Gisa Ellrichmann; Mark Stettner; Andrew Chan; Hans-Peter Hartung; Bernd Kieseier; Ralf Gold; Orhan Aktas; Ingo Kleiter
Journal:  JAMA Neurol       Date:  2015-07       Impact factor: 18.302

3.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Authors:  Sean J Pittock; Achim Berthele; Kazuo Fujihara; Ho Jin Kim; Michael Levy; Jacqueline Palace; Ichiro Nakashima; Murat Terzi; Natalia Totolyan; Shanthi Viswanathan; Kai-Chen Wang; Amy Pace; Kenji P Fujita; Róisín Armstrong; Dean M Wingerchuk
Journal:  N Engl J Med       Date:  2019-05-03       Impact factor: 91.245

4.  Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.

Authors:  Anthony Traboulsee; Benjamin M Greenberg; Jeffrey L Bennett; Lech Szczechowski; Edward Fox; Svitlana Shkrobot; Takashi Yamamura; Yusuke Terada; Yuichi Kawata; Padraig Wright; Athos Gianella-Borradori; Hideki Garren; Brian G Weinshenker
Journal:  Lancet Neurol       Date:  2020-05       Impact factor: 44.182

5.  Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.

Authors:  Chao Zhang; Meini Zhang; Wei Qiu; Hongshan Ma; Xinghu Zhang; Zilong Zhu; Chun-Sheng Yang; Dongmei Jia; Tian-Xiang Zhang; Meng Yuan; Yan Feng; Li Yang; Wenli Lu; Chunshui Yu; Jeffrey L Bennett; Fu-Dong Shi
Journal:  Lancet Neurol       Date:  2020-05       Impact factor: 44.182

6.  Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.

Authors:  Manabu Araki; Takako Matsuoka; Katsuichi Miyamoto; Susumu Kusunoki; Tomoko Okamoto; Miho Murata; Sachiko Miyake; Toshimasa Aranami; Takashi Yamamura
Journal:  Neurology       Date:  2014-03-14       Impact factor: 9.910

7.  What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.

Authors:  Shahd H M Hamid; Daniel Whittam; Kerry Mutch; Samantha Linaker; Tom Solomon; Kumar Das; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-08-24       Impact factor: 4.849

Review 8.  Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.

Authors:  Kazuo Fujihara; Jeffrey L Bennett; Jerome de Seze; Masayuki Haramura; Ingo Kleiter; Brian G Weinshenker; Delene Kang; Tabasum Mughal; Takashi Yamamura
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-08-20

9.  Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.

Authors:  Maria Sepúlveda; Thaís Armangué; Nuria Sola-Valls; Georgina Arrambide; José E Meca-Lallana; Celia Oreja-Guevara; Mar Mendibe; Amaya Alvarez de Arcaya; Yolanda Aladro; Bonaventura Casanova; Javier Olascoaga; Adolfo Jiménez-Huete; Mireya Fernández-Fournier; Lluis Ramió-Torrentà; Alvaro Cobo-Calvo; Montserrat Viñals; Clara de Andrés; Virginia Meca-Lallana; Angeles Cervelló; Carmen Calles; Manuel Barón Rubio; Cristina Ramo-Tello; Ana Caminero; Elvira Munteis; Alfredo R Antigüedad; Yolanda Blanco; Pablo Villoslada; Xavier Montalban; Francesc Graus; Albert Saiz
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-04-14

10.  The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody.

Authors:  Romana Höftberger; Yong Guo; Eoin P Flanagan; A Sebastian Lopez-Chiriboga; Verena Endmayr; Sonja Hochmeister; Damir Joldic; Sean J Pittock; Jan Mendelt Tillema; Mark Gorman; Hans Lassmann; Claudia F Lucchinetti
Journal:  Acta Neuropathol       Date:  2020-02-11       Impact factor: 17.088
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.